{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:07:56Z","timestamp":1740107276544,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00415-019-09531-6","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T18:06:51Z","timestamp":1568830011000},"page":"3098-3107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register"],"prefix":"10.1007","volume":"266","author":[{"name":"the Italian MS Register","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8645-1763","authenticated-orcid":false,"given":"Damiano","family":"Paolicelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lucisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Manni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Conte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"De Robertis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizia","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Gazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Lus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Iaffaldano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Iaffaldano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Maimone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Mallucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia T.","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girolama A.","family":"Marfia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Pesci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Rovaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Salemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Spitaleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Totaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Trojano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,18]]},"reference":[{"issue":"5","key":"9531_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1017\/cjn.2018.17","volume":"45","author":"MS Freedman","year":"2018","unstructured":"Freedman MS, Selchen D, Prat A, Giacomini PS (2018) Managing multiple sclerosis: treatment initiation, modification, and sequencing. Can J Neurol Sci 45(5):489\u2013503","journal-title":"Can J Neurol Sci"},{"issue":"6","key":"9531_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","volume":"31","author":"J Oh","year":"2018","unstructured":"Oh J, Vidal-Jordana A, Montalban X (2018) Multiple sclerosis: clinical aspects. Curr Opin Neurol 31(6):752\u2013759","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"9531_CR3","first-page":"715","volume":"25","author":"RH Gross","year":"2019","unstructured":"Gross RH, Corboy JR (2019) Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies. Continuum (Minneap Minn) 25(3):715\u2013735","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"9531_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nrneurol.2014.237","volume":"11","author":"MP Sormani","year":"2015","unstructured":"Sormani MP, Bruzzi P (2015) Can we measure long-term treatment effects in multiple sclerosis? Nat Rev Neurol 11(3):176\u2013182","journal-title":"Nat Rev Neurol"},{"key":"9531_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.msard.2016.01.007","volume":"6","author":"A Signori","year":"2016","unstructured":"Signori A, Gallo F, Bovis F et al (2016) Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord 6:57\u201363","journal-title":"Mult Scler Relat Disord"},{"key":"9531_CR6","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/jnnp-2014-310024","volume":"86","author":"L Kappos","year":"2015","unstructured":"Kappos L, Kuhle J, Multanen J et al (2015) Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15. J Neurol Neurosurg Psychiatry 86:1202\u20131207","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9531_CR7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40263-016-0377-9","volume":"30","author":"D Mendes","year":"2016","unstructured":"Mendes D, Alves C, Batel-Marques F (2016) Benefit-risk of therapies for relapsing\u2013remitting multiple sclerosis: testing the number needed to treat to benefit (NNTB), number needed to treat to harm (NNTH) and the likelihood to be helped or harmed (LHH): a systematic review and meta-analysis. CNS Drugs 30:909\u2013929","journal-title":"CNS Drugs"},{"key":"9531_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402\u2013415","journal-title":"N Engl J Med"},{"key":"9531_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O'Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387\u2013401","journal-title":"N Engl J Med"},{"key":"9531_CR10","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1212\/WNL.0000000000001462","volume":"84","author":"L Kappos","year":"2015","unstructured":"Kappos L, O'Connor P, Radue EW et al (2015) Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology 84:1582\u20131591","journal-title":"Neurology"},{"key":"9531_CR11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/jnnp-2015-310597","volume":"87","author":"JA Cohen","year":"2016","unstructured":"Cohen JA, Khatri B, Barkhof F et al (2016) Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry 87:468\u2013475","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9531_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10072-018-3610-0","volume":"40","author":"M Trojano","year":"2019","unstructured":"Trojano M, Bergamaschi R, Amato MP et al (2019) The Italian multiple sclerosis register. Neurol Sci 40:155\u2013165","journal-title":"Neurol Sci"},{"key":"9531_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292\u2013302","journal-title":"Ann Neurol"},{"key":"9531_CR14","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","volume":"264","author":"G Pardo","year":"2017","unstructured":"Pardo G, Jones DE (2017) The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol 264:2351\u20132374","journal-title":"J Neurol"},{"key":"9531_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ et al (2018) ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24:96\u2013120","journal-title":"Mult Scler"},{"key":"9531_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA et al (2018) Practice guideline recommendations summary: disease- modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90:777\u2013788","journal-title":"Neurology"},{"key":"9531_CR17","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","volume":"389","author":"G Comi","year":"2017","unstructured":"Comi G, Radaelli M, Soelberg S\u00f8rensen P (2017) Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet 389:1347\u20131356","journal-title":"Lancet"},{"key":"9531_CR18","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1212\/WNL.0000000000005574","volume":"90","author":"JR Corboy","year":"2018","unstructured":"Corboy JR, Weinshenker BG, Wingerchuk DM (2018) Comment on 2018 American Academy of Neurology guidelines on disease- modifying therapies in MS. Neurology 90:1106\u20131112","journal-title":"Neurology"},{"key":"9531_CR19","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1177\/1352458509104591","volume":"15","author":"J Rio","year":"2009","unstructured":"Rio J, Castill\u00f3 J, Rovira A et al (2009) Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 15:848\u2013853","journal-title":"Mult Scler"},{"key":"9531_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/1352458512460605","volume":"19","author":"MP Sormani","year":"2013","unstructured":"Sormani MP, Rio J, Tintor\u00e8 M et al (2013) Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 19:605\u2013612","journal-title":"Mult Scler"},{"key":"9531_CR21","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3111\/13696998.2012.693553","volume":"15","author":"S Lee","year":"2012","unstructured":"Lee S, Baxter DC, Limone B et al (2012) Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. J Med Econ 15:1088\u20131096","journal-title":"J Med Econ"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09531-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09531-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09531-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T01:36:08Z","timestamp":1600306568000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09531-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,18]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["9531"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09531-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2019,9,18]]},"assertion":[{"value":"11 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G. Lucisano, A. Manni, S. Bonavita, V. Brescia Morra, A. Conte, F. De Robertis, P. Gazzola, A. Iaffaldano, C. Gasperini, M. Gatto, G.T. Maniscalco, I. Pesci report no disclosures relevant to the manuscript. D. Paolicelli received advisory board membership, speakers honoraria, travel support, research grants, consulting fees, or clinical trial support from Almirall, Bayer Schering, Biogen, Celgene, Excemed, Genzyme, Merck, Mylan, Novartis, Sanofi, Roche, Teva. M.P. Amato has received research grants and honoraria as a speaker and member of advisory boards by Biogen, Merck, Sanofi Genzyme, Teva, Novartis, Roche. C. Avolio served on scientific advisory boards for Merck, Sanofi-Genzyme and Roche, and has received travel and\/or speaker honoraria from Merck, Roche, Teva, Biogen, Novartis and Sanofi-Genzyme. M. Capobianco received personal compensation for speaking at meeting or participating in advisory board from Almirall, Biogen, Merck, Novartis, Sanofi, Roche. E. Cocco has served on scientific Advisory Boards for Bayer, Biogen, Merck, Novartis, Roche, Sanofi Genzyme and TEVA; she also received speaker honoraria and research grants for her department by the same companies. G. Comi received personal compensation for consulting services and\/or speaking activities from Novartis, Teva, Sanofi, Sanofi-Genzyme, Merck, Biogen, Excemed, Serono Symposia International Foundation, Roche, Almirall, Receptos, Celgene, and Forward Pharma. G. De Luca served on scientific advisory boards for Merck, Sanofi-Genzyme and Roche, and has received travel and\/or speaker honoraria from Merck, Roche, Teva, Biogen, Novartis and Sanofi-Genzyme. G. Lus receveid travel fundings, research support, speaker honoraria from: Biogen, Novartis, Sanofi Genzyme, Bayer, Teva, Almirall, Allergan, Ipsen, Merck, Merz Pharma Italia. P. Iaffaldano received advisory board membership, speaker honoraria, travel support, research grants, consulting fees, or clinical trial support from Almirall, Bayer Schering, Biogen, Celgene, Excemed, Genzyme, Merck, Mylan, Novartis, Sanofi, Roche, Teva. D. Maimone receveid travel funds and speaker honoraria from Biogen, Novartis, Sanofi Genzyme, Teva, Almirall, Merck, Roche. G. Mallucci received support to travel to scientific meetings from Bayer Schering, Biogen, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis, Teva; received research grants for the MS Center at IRCCS Mondino, Pavia, Italy from Biogen and served on the scientific advisory board for Biogen, Genzyme and Merck Serono. G.A. Marfia is an Advisory Board member of Biogen Idec, Genzyme, Merck-Serono, Novartis, Teva and received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme, Teva. She is the principal investigator in clinical trials for Actelion, Biogen Idec, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi-Genzyme, Teva. F. Patti has received honoraria for speaking activities by Bayer Schering, Biogen, Merck, Novartis, Roche, TEVA and Sanofi Aventis; he also served as advisory board member the following companies: Bayer Schering, Roche, Biogen, Merck, Novartis; he was also funded by Pfizer and FISM for epidemiological studies; finally he received grant for congress participation from Bayer Schering, Roche, Biogen, Merck, Novartis, Sanofi Aventis, and TEVA. C. Pozzilli has received consultant fees from Actelion, Biogen, Genzyme, Merck-Serono, Novartis, Teva Neurosciences and grant or research support from Biogen, Merck-serono, Novartis and Teva neuroscinces. M. Rovaris received fees for consulting or scientific speaking from Almirall, Biogen, Genzyme-Sanofi, Merck Serono and TEVA. G. Salemi received grants and honoraria by Almirall, Biogen-Domp\u00e8, Merck-Serono, Novartis, Roche, Sanofi-Aventis, and TEVA. M. Salvetti received research support and consulting fees from Biogen, Merck, Novartis, Roche, Sanofi, Teva. D. Spitaleri received fees for consulting or congress participation from Novartis, TEVA, Sanofi and Biogen. R. Totaro has served on advisory boards and\/or received honoraria for speaking or consultation fees from Biogen, CSL behring, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, Shire, Teva. M. Zaffaroni received personal financial support for attending scientific meetings from Merck and financial support for his Department from Novartis. M. Trojano received advisory board membership, speaker honoraria, travel support, research grants, consulting fees, or clinical trial support from Actelion, Allergan, Almirall, Bayer Schering, Biogen, Celgene, Excemed, Genzyme, Merck, Mylan, Novartis, Sanofi, Roche, Teva.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975. The study was approved by the Ethic Committee of AOU Policlinico, Bari on 17 July 2018; ID number 0060669.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval"}}]}}